Project: Research project

Project Details


The number of patients diagnosed with prostate cancer has increased 63%
in the last 7 years. Over the same time period, the number of deaths
has risen from 24,000 to 32,000 cases a year. With the aging of the
American male population, these figures can only be expected to increase
over the coming years. The answer to lowering the mortality from this
disease depends upon our ability to determine its malignant potential,
to learn why it is a more aggressive disease in African-Americans that
whites, and to determine what governs its response or lack thereof to
hormonal therapy. Our hypothesis continues to be that genetic
abnormalities will be found at either the RNA or DNA level that
determine the natural history of carcinoma of the prostate (CaP). Our
studies will continue to identify and assess the prevalence of these
genetic abnormalities, or their manifestations, in benign, premalignant,
and malignant prostate tissues. We will continue to characterize CaP by
using the polymerase chain reaction technique, focusing on studies of
p53, Rb-1, nm23, hAR, and ras. Selected samples will then be sequenced
in order to determine point mutations. We will, over the grant period,
expand our studies to include the techniques of DGGE and subtractive
hybridization. We will continue to develop tissue culture capabilities
in order to supply samples of both hormonally-manipulated amd
unmanipulated tissue for our molecular studies. The chance of success
in these endeavors will be greatly enhanced by being a member of the
proposed cooperative network, since this will allow for interchange of
ideas, materials, and techniques. Thus, it will be possible to much
more rapidly validate findings from individual laboratories by comparing
results of the molecular tests with each other and to known clinical
parameters. Evaluation of the molecular studies, both individually and
collectively, will be accelerated, leading to a more rapid, cost-
effective characterization of CaP and, from there, to answers to the
questions posed in the RFA.
Effective start/end date7/20/926/30/97


  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health


  • Medicine(all)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.